Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RP2/RP3 with atezolizumab and bevacizumab in MSS/pMMR colorectal cancer
NCT05733611Phase 2Terminated
- Sponsor
- Replimune Group, Inc.
- Start
- Jun 2023
- Primary completion
- Aug 2025
- Modality
- Gene Editing, Antibody Conjugates, Gene Silencing
- Countries
- 1
01
Overview
A Phase 2 trial of sturlimogene erparepvec, RP3 in colorectal carcinoma (CRC), sponsored by Replimune Group, Inc.. Started Jun 2023; status: terminated.
02
Drugs
sturlimogene erparepvecRP3
03
Conditions
colorectal carcinoma (CRC)
Beyond the preview
Go deeper on NCT05733611.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05733611.